Abstract: The present invention relates to antibodies and antigen binding fragment thereof, capable of binding to CD38 antigen. More specifically, the invention relates to antibodies and antigen binding fragments, wherein said antibodies or antigen binding fragments comprises sequences of human origin, and wherein said sequences of human origin reduces immunogenicity compared to a murine antibody. The invention further relates to bispecific antibodies for binding to CD38 and CD3. Further, the invention relates to bispecific antibodies for binding to CD38 and a chelator. The invention further relates to antibodies and antigen binding fragments for the treatment of cancer and autoimmune diseases.

Abstract: The present invention relates to humanized antibodies and antigen binding fragments. More specifically, the invention relates to humanized antibodies and antigen binding fragment, capable of binding to antigens, wherein said antibodies or antigen binding fragments comprises at least 50% amino acids that are identical to the amino acids of the human germline of said antibody or antigen binding fragment. The present invention further relates to antibodies with minimal potential for immunogenicity by intraperitoneal or systemic administration to treat B7-H3(+) solid tumors. The invention further relates to fully humanized antibodies against B7-H3 with high human content, strong binding to B7-H3, high stability, high purity, and high expression titers.

Abstract: The present invention relates to B7H3-antibodies conjugated to specific chelators for radiolabeling with imaging or therapeutic radioisotopes. The invention further relates to B7H3-antibodies for treatment or theranostic use in cancer.